| Market Cap | 315.94M | P/E | 19.64 | EPS this Y | -1,325.00% | Ern Qtrly Grth | - |
| Income | -10.93M | Forward P/E | -32.35 | EPS next Y | 153.10% | 50D Avg Chg | -12.00% |
| Sales | 182.02M | PEG | -0.27 | EPS past 5Y | -16.70% | 200D Avg Chg | -26.00% |
| Dividend | N/A | Price/Book | 0.59 | EPS next 5Y | 36.10% | 52W High Chg | -50.00% |
| Recommedations | 2.30 | Quick Ratio | 4.58 | Shares Outstanding | 58.29M | 52W Low Chg | - |
| Insider Own | 3.16% | ROA | -3.14% | Shares Float | 52.51M | Beta | 0.78 |
| Inst Own | 77.53% | ROE | -2.02% | Shares Shorted/Prior | 3.35M/3.15M | Price | 5.50 |
| Gross Margin | 93.03% | Profit Margin | -6.00% | Avg. Volume | 586,569 | Target Price | 8.07 |
| Oper. Margin | -20.10% | Earnings Date | Nov 6 | Volume | 622,323 | Change | -2.48% |
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
| Cantor Fitzgerald | Overweight | Aug 1, 24 |
| Cantor Fitzgerald | Overweight | Jul 11, 24 |
| Jefferies | Hold | Feb 25, 22 |
| B of A Securities | Buy | May 12, 21 |
| Citigroup | Neutral | Jan 14, 21 |
| Citigroup | Buy | Oct 29, 20 |
| Citigroup | Neutral | Jun 9, 20 |
| Citigroup | Buy | Mar 12, 20 |
| Stifel | Hold | Feb 26, 20 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Wijkstrom Joakim | SVP, Chief Marketing.. SVP, Chief Marketing Officer | Aug 21 | Sell | 5.84 | 3,724 | 21,748 | 113,816 | 08/23/23 |
| Polymeropoulos Mihael Hristos | President and CEO President and CEO | Dec 05 | Option | 3.12 | 150,000 | 468,000 | 1,455,116 | 12/07/22 |
| Polymeropoulos Mihael Hristos | President and CEO President and CEO | Dec 05 | Sell | 10.62 | 95,900 | 1,018,458 | 1,406,866 | 12/07/22 |
| Moran Kevin Patrick | SVP, CFO & Treasurer SVP, CFO & Treasurer | Dec 06 | Option | 3.12 | 7,500 | 23,400 | 124,952 | 12/07/22 |
| Moran Kevin Patrick | SVP, CFO & Treasurer SVP, CFO & Treasurer | Dec 06 | Sell | 10.61 | 4,792 | 50,843 | 120,160 | 12/07/22 |
| Birznieks Gunther | SVP, Business Develo.. SVP, Business Development | Aug 26 | Option | 3.12 | 1,250 | 3,900 | 190,057 | 08/29/22 |
| Wijkstrom Joakim | SVP, Chief Marketing.. SVP, Chief Marketing Officer | Aug 22 | Sell | 10.2656 | 3,605 | 37,007 | 96,673 | 08/23/22 |
| Moran Kevin Patrick | SVP, CFO & Treasurer SVP, CFO & Treasurer | Jul 28 | Sell | 10.97 | 2,239 | 24,562 | 117,452 | 08/01/22 |
| Mitchell Stephen Ray | Director Director | Jun 13 | Sell | 9.4789 | 2,700 | 25,593 | 6,515 | 06/14/22 |
| Williams Timothy | SVP & General Counse.. SVP & General Counsel | Feb 28 | Sell | 11.09 | 12,060 | 133,745 | 103,851 | 03/02/22 |
| Wijkstrom Joakim | SVP, Chief Marketing.. SVP, Chief Marketing Officer | Feb 28 | Sell | 11.19 | 6,974 | 78,039 | 100,278 | 03/02/22 |
| Polymeropoulos Mihael Hristos | President and CEO President and CEO | Feb 28 | Sell | 11.17 | 37,096 | 414,362 | 1,352,766 | 03/02/22 |
| Moran Kevin Patrick | SVP, CFO & Treasurer SVP, CFO & Treasurer | Feb 28 | Sell | 11.24 | 12,305 | 138,308 | 119,691 | 03/02/22 |
| Birznieks Gunther | SVP, Business Develo.. SVP, Business Development | Feb 28 | Sell | 11.23 | 15,601 | 175,199 | 188,807 | 03/02/22 |
| Jones Aranthan II | Chief Corp. Affairs.. Chief Corp. Affairs Officer | Sep 17 | Sell | 16.49 | 16,824 | 277,428 | 81,980 | 09/17/21 |
| Jones Aranthan II | Chief Corp. Affairs.. Chief Corp. Affairs Officer | Sep 17 | Option | 11.8 | 12,119 | 143,004 | 98,804 | 09/17/21 |
| Williams Timothy | SVP & General Counse.. SVP & General Counsel | Mar 03 | Sell | 18.57 | 19,530 | 362,672 | 92,526 | 03/03/21 |
| Watkins Thomas | Director Director | Feb 18 | Option | 7.11 | 15,000 | 106,650 | 55,323 | 02/18/21 |
| Watkins Thomas | Director Director | Feb 18 | Sell | 18.54 | 5,818 | 107,866 | 49,505 | 02/18/21 |
| DUGAN RICHARD W | Director Director | Feb 18 | Option | 7.11 | 15,000 | 106,650 | 60,641 | 02/18/21 |
| DUGAN RICHARD W | Director Director | Feb 18 | Sell | 18.54 | 5,754 | 106,679 | 54,887 | 02/18/21 |